United States of America
Dr. Mang Yu, also known as Mark, Ph.D. has been Managing Partner for Forward Pacific Ventures at Forward Ventures. Dr. Yu joined Forward Ventures in 2015 to direct its efforts to organize a cross-border program involving Asia and China, in particular. He Co-Founded Ansun Biopharma, Inc. in 2003 and served as its Chief Executive Officer and President. Dr. Yu Co-founded Perlan Therapeutics and served as its Executive Vice President. While at Perlan, Dr. Yu successfully raised multiple rounds of venture capital that supported the Perlan's development of ColdSol(TM) for the prevention and treatment of the common cold caused by human rhinovirus. Under his leadership, ColdSol(TM) won the Most Innovative New Product (MIP) Award in 2002. Dr. Yu Co-founded Immusol, Inc., where he served as Director of HIV Gene Therapy, and as Director of Target Discovery & Gene Therapy (for HIV, HBV, & HCV). While at Immusol, Dr. Yu was responsible for a corporate partnership with Pfizer on an anti-HIV drug, MY-2. He serves as the Chairman of the Board of Ansun Biopharma, Inc. He served as a Director of Global 2.0 Corporation (Alternate name: Global Seafood Holdings Corporation) from April 2006 to April 14, 2008. Dr. Yu was a founding board member of BayHelix. He serves as Honorable Chairman of the Business Advisory Council for the NRCC. Before his immigration to U.S. in 1985, Dr. Yu served as Assistant Professor at the Shanghai Medical University. He is an annual guest speaker on bio- entrepreneurship for MBA class at San Diego State University. He received his BS and MS degrees from Fudan University. Dr. Yu holds a Ph.D. in Biochemistry and Molecular Biology from Indiana University, School of Medicine, and completed his post-doctoral training at University of California, San Diego.